Skip to main content

Advertisement

SpringerLink
Log in

Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Higher incidence of adverse drug reactions (ADRs) remain a major cause of morbidity and mortality. Most targeted ADR reporting activities are mainly professional-centered with less attention to patients’ knowledge, perception and selfreporting of experienced ADRs. Objectives To comprehensively evaluate patients’ knowledge, awareness, perception and reporting of experienced ADRs. Setting Three public healthcare facilities in Ibadan, southwestern Nigeria. Method A questionnaire-guided cross-sectional interview of 1190 consented ambulatory adult patients consecutively recruited from various clinics of the selected hospitals between February and June 2018. The 32-item pretested questionnaire comprised open- and closed-ended questions, as well as open-ended questions with relevant prompts. Data were summarised using descriptive statistics, while Chi square was used to investigate association between relevant categorical variables at p < 0.05. Main outcome measure Knowledge, awareness, perception and reporting of experienced ADRs among patients. Results Response rate was 99.1%. Mean age was 40.6 ± 14.9 years. Forty-nine (4.1%) patients were aware of pharmacovigilance. A total of 964 (81.0%) correctly understood what can be regarded as serious adverse drug reactions (ADRs), 444 (37.3%) had previously experienced ADRs, while 77 (6.5%) experienced reactions with current medication(s). Of this, 64 (83.1%) made a report largely to physician (52; 81.3%). Summarily, reported reactions were more with antimalarials (214; 49.1%), with itching (168; 78.5%) constituting the most frequently occurring reaction. Use of text message (276; 27.2%) and filling of ADR report form (248; 24.4%) were topmost on the list of suggested methods for ADR reporting. There was a significant association between patient’s age and awareness of pharmacovigilance (p = 0.015), while educational qualification (p = 0.001) significantly influenced tendency to make a report of experienced ADRs. Conclusion Approximately four percent of patients were aware of pharmacovigilance, while more than three-quarters correctly understood the concept of serious adverse drug reactions. A little above one-quarter had previously experienced one form of reaction or the other, with majority reporting such reactions to physician. Continuous education of stakeholders in pharmacovigilance activities is advocated, while patient’s active involvement in spontaneous reporting of ADRs should be carefully considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse drug reaction related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39:847–57.

    Article  CAS  PubMed  Google Scholar 

  2. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States vital statistics, 1999–2000. Ann Pharmacother. 2012;46:169–75.

    Article  PubMed  Google Scholar 

  3. Pirmohamed M, Breckenridge A, Kitteringham N, Park B. Adverse drug reactions. Br Med J. 1998;316:1295–8.

    Article  CAS  Google Scholar 

  4. Roughhead L, Semple S, Rosenfeld E. Australian Commission on safety and quality in healthcare. In: Roughhead L, Semple S, Rosenfield E, editors. Literature review: medication safety in Australia. Sydney: ACSQHC; 2013.

    Google Scholar 

  5. Lindquist M. Data quality management in pharmacovigilance. Drug Saf. 2004;27:857–70.

    Article  PubMed  Google Scholar 

  6. Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, et al. Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000;22:161–8.

    Article  CAS  PubMed  Google Scholar 

  7. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products. United kingdom. 2002. http://apps.who.int/medicinedocs/pdf/s4893e.pdf. Accessed 29 Jan 2019.

  10. Meyboom R, Olsson S, Thorogood M. Teaching pharmacovigilance. In: Mann R, Andrews E, editors. pharmacovigilance. Chichester: Wiley; 2002. p. 505–8.

    Google Scholar 

  11. Li Q, Zhang S, Chen H, Fang S, Yu X, Liu D, et al. Awareness and attitudes of healthcare professionals in Wuhan, China to the reporting of adverse drug reactions. Chin Med J. 2004;117:856–61 (Engl).

    PubMed  Google Scholar 

  12. Durrieu G, Jacquot J, Mege M, Bondon-Guitton E, Rousseau V, Montastrue F, et al. Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study. Drug Saf. 2016;39:1189–95.

    Article  CAS  PubMed  Google Scholar 

  13. Inacio P, Cavaco A, Airaksinen M. Current trends in pharmacovigilance: value and gaps of patient reporting. Int J Clin Pharm. 2018;40:754–7.

    Article  PubMed  Google Scholar 

  14. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75–81.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sottosanti L. Current role of the patients in pharmacovigilance activities: regulatory perspective. http://congresso.sifweb.org/programma/abs/102.pdf. Accessed 29 Jan 2019.

  16. van Hunsel F. The contribution of direct patient reporting to pharmacovigilance. Dissertation on the internet, Netherlands: University of Groningen. 2011. http://www.lareb.nl/media/3026/2011_4_thesis_patient_reporting.pdf. Accessed 29 Jan 2019.

  17. Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. Drug Saf. 2014;37(6):409–19.

    Article  CAS  PubMed  Google Scholar 

  18. Kumar V. Challenges and future considerations for pharmacovigilance. J Pharmacovigil. 2013;1:1–3.

    Article  Google Scholar 

  19. Jha N, Rathore DS, Shankar PR, Thaga BB, Bhuju G, Alshakka M. Need for involving consumers in Nepal’s pharmacovigilance system. Aust Med J. 2014;7(4):191–5.

    Article  Google Scholar 

  20. Elshafie S, Zaghloul I, Robert AM. Pharmacovigilance in developing countries (part 1): importance and challenges. Int J Clin Pharm. 2018;40:758–63.

    Article  PubMed  Google Scholar 

  21. Matos C, Harmark L, van Hansel F. Patient reporting of adverse drug reactiions: an international survey of national competent authorities’ views and needs. Drug Saf. 2016;39:1105–16.

    Article  CAS  PubMed  Google Scholar 

  22. van Grootheest K, de Graaf L, de Jong-van den Berg LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance. Drug Saf. 2003;26:211–7.

    Article  PubMed  Google Scholar 

  23. Watson S, Chandler RE, Taavola H, Harmark I, Grundmark B, Zakarias A, et al. Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflection from Lareb and Uppsala monitoring centre. Drug Saf. 2018;14:203–12.

    Article  Google Scholar 

  24. Edwards IR, Lindquist M. Social media and networks in pharmacovigilance: boon or bane? Drug Saf. 2011;34(4):267–71.

    Article  PubMed  Google Scholar 

  25. Jose J, AlHajri L. Potential negative impact of informing patients about medication side effects: a systematic review. Int J Clin Pharm. 2018;40:806–22.

    Article  PubMed  Google Scholar 

  26. Inacio P, Cavaco A, Airaksimen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83(2):227–46.

    Article  PubMed  Google Scholar 

  27. van Hunsel F, de Waal S, Harmark L. The contribution of direct patient reported ADRs to drug safety signal in the Netherlands from 2010 to 2015. Pharmacoepidemiol Drug Saf. 2017;26:977–83.

    Article  PubMed  Google Scholar 

  28. Enwere OO, Fawole OI. Adverse drug reactions reporting by physicians in Ibadan Nigeria. Pharmacoepidemiol Drug Saf. 2008;17(5):517–22.

    Article  Google Scholar 

  29. Okechukwu RC, Odinduka SO, Ele GN, Okonta MJ. Awareness, attitude, and practice of pharmacovigilance among health care professionals in Nigeria: survey in a teaching hospital. Int J Hosp Res. 2013;2(3):99–108.

    Google Scholar 

  30. Oreagba IA, Ogunleye OJ, Olayemi SO. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, South-West Nigeria. Pharmacoepidemiol Drug Saf. 2011;20(1):30–5.

    Article  CAS  PubMed  Google Scholar 

  31. Chatterjee S, Lyle N, Ghosh S. A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in eastern India. Drug Saf. 2006;29(7):641–3.

    Article  PubMed  Google Scholar 

  32. Adimasu A. Nurses knowledge related to adverse drug reaction reporting and associated factors at Felegehiwot Referral Hospital and University of Gondar Teaching Hospital, Northwestern Ethiopia. Am J Health Res. 2014;2:164–70.

    Article  Google Scholar 

  33. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Elshafie S, Robert AM, Zaghloul I. Pharmacovigilance in developing countries (part II): a path forward. Int J Clin Pharm. 2018;40:764–8.

    Article  PubMed  Google Scholar 

  35. Raosoft Sample Size Calculator. http://www.raosoft.com/samplesize.html. Accessed 20 Dec 2018.

  36. Bawazir SA. Community pharmacists in Saudi Arabia towards adverse drug reactions reporting. Saudi Pharm J. 2006;14:75–93.

    Google Scholar 

  37. Alraie NA, Saad AA, Sabry NA, Farid SF. Adverse drug reactions reporting: a questionnaire-based study on Egyptian pharmacists’ attitudes following an awareness workshop. J Eval Clin Pract. 2015;22(3):349–55.

    Article  PubMed  Google Scholar 

  38. Seid AM, Kasahun AE, Mante BM, Gebremariam SN. Healthcare professionals’ knowledge, attitude and practice towards adverse drug reaction (ADR) reporting at the health center level in Ethiopia. Int J Clin Pharm. 2018;40:895–902.

    Article  PubMed  Google Scholar 

  39. Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018;40:878–89.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Peters E, Hart PS, Fraenkel L. Informing patients: the influence of numeracy, framing, and format of side effect information on risk perceptions. Med Decis Mak. 2011;31(3):432–6.

    Article  Google Scholar 

  41. Diaz JA, Griffith RA, Ng JJ, Reinert SE, Friedmann PD, Moulton AW. Patients’ use of the internet for medical information. J Gen Intern Med. 2002;17(3):180–5.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Jose J, Jimmy B, Al-Mamari MN, Al-Hadrami TS, Al-Zadjal HM. Knowledge, beliefs and behaviours regarding the adverse effects of medicines in an Oman population cross-section survey. Sultan Oaboos Univ Med J. 2015;15(2):E250–6.

    Google Scholar 

  43. Appiah B. Africa’s struggles to improve drug safety. CMAJ. 2012;184(10):E533–4.

    Article  PubMed  PubMed Central  Google Scholar 

  44. National Agency for Food and Drug Administration and Control (NAFDAC) official website. Nigeria Regulations. http://www.nafdac.gov.ng/index.php/regulation/161-faqs. Accessed 28 Dec 2019.

  45. Ogar CK, Ibrahim A, Osakwe AI, Jajare F, Kigbu-Adekunle AA, Alonge K, Oni Y. Pharmacovigilance rapid alert system for consumer reporting (PRASCOR): a look at its quantitative contribution to spontaneous reporting in Nigeria from August 2012 to February 2017. Pharm Med. 2018;32(2):131–41.

    Article  Google Scholar 

  46. Huff-Rouselle M, Simmoya O, Kabwe V, Hollander I, Handema R, Nwango A, Mwanpe E. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Glob Public Health. 2007;2(2):184–203.

    Article  Google Scholar 

  47. Aagaard L, Nielsen LH, Hansen BH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32(11):1067–74.

    Article  PubMed  Google Scholar 

  48. Jarernsiripornkul N, Krska J, Capps PAG, Richards RME, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol. 2002;53(3):318–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Xu H, Wang Y, Liu N. A hospital based survey of healthcare professionals in the awareness of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2009;18:624–30.

    Article  PubMed  Google Scholar 

  50. Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinion s regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19:217–22.

    Article  PubMed  Google Scholar 

  51. Suyagh M, Farah D, Farha RA. Pharmacist’s knowledge, practice, and perspectives toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J. 2015;23(2):147–53.

    Article  PubMed  Google Scholar 

  52. Hendero MT, Polonia J, Gestal-Otero J, Figueiras A. Improving the reporting of adverse drug reactions: a cluster randomized trial among pharmacists in Portugal. Drug Saf. 2008;31:335–44.

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge and appreciate the cooperation of all patients who participated in this study.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan, Ibadan, Nigeria

    Rasaq Adisa, Omotola Rukayat Adeniyi & Titilayo Oyelola Fakeye

Authors
  1. Rasaq Adisa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omotola Rukayat Adeniyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Titilayo Oyelola Fakeye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rasaq Adisa.

Ethics declarations

Conflicts of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 76 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adisa, R., Adeniyi, O.R. & Fakeye, T.O. Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. Int J Clin Pharm 41, 1062–1073 (2019). https://doi.org/10.1007/s11096-019-00849-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00849-9

Keywords

Search

Navigation